<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02598830</url>
  </required_header>
  <id_info>
    <org_study_id>Trainsome 2014#004</org_study_id>
    <nct_id>NCT02598830</nct_id>
  </id_info>
  <brief_title>The Granheim COPD Study - Vitamin D and Strength Training</brief_title>
  <official_title>The Granheim COPD Study: Effects of Vitamin D3-supplementation on the Efficacy of Strength Training in COPD Patients and Healthy Controls - a Double-blinded RCT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inland Norway University of Applied Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sykehuset Innlandet HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lillehammer Hospital for Rheumatic Diseases</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Bergen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norwegian School of Sport Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Inland Norway University of Applied Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effect of vitamin D supplementation on outcomes of 10 weeks
      progressive strength training in 100 ageing subjects (&gt;45 years of age). Participants will be
      recruited into two similarly sized strata; one containing COPD patients and one containing
      healthy subjects of similar age. In each stratum, half the participants will receive vitamin
      D supplementation and half the participants will receive placebo
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Physical activity is a potent way of relieving some of the adverse morbidities associated
      with COPD, such as muscle atrophy and reduced muscle quality. It is thus problematic that
      20-30% of patients fail to elicit positive adaptations to training. This oddity has been
      ascribed inherent muscular properties, with potential links to comorbidities such as vitamin
      D and testosterone deficiency and the nature of the training program. In the present project,
      a double-blinded RCT will be performed to disclose the functional and biological efficacy of
      vitamin D supplementation (with concomitant ingestion of 1000 mg Ca2+) on the outcomes of 10
      wks strength training in 100 aging individuals with or without COPD. The strength training
      intervention will be preceded by 3 weeks of progressive introduction to training protocols.

      50 COPD patients and 50 healthy subjects will be allocated into two strata and separately
      randomized into two equally sized supplementation groups; (1) vitamin D3 and (2) placebo. The
      planned 50:50 ratio between COPD patients and healthy individuals may change, depending on
      the access to COPD patients. All subjects will perform lower-limb strength-training protocols
      in a contralateral manner: (leg 1) high-resistance (10 RM) and (leg 2) low-resistance (30
      RM). Such a one-limb-at-a-time protocol ensures training that is unconfined by the
      cardiorespiratory limitations inherent to these patients, and allow comparison of the two
      training modalities in a manner unconfined by individual variation in exercise adaptability.
      A pilot study investigating the possible central pulmonary capacity limitation to two-legged
      strength training exercise in COPD patients will be performed. In this pilot study, we will
      compare exercise performance involving large and small muscle mass. In addition, all subjects
      will perform a selection of bilateral upper body exercises (10 RM), ensuring adequate
      hormonal responses and compliance to the study. The study is likely to revitalize guidelines
      for rehabilitation of COPD patients, and to provide vital information regarding the role of
      vitamin D in adaptations to strength training.

      For outcome measures specific to COPD pasients, final analyses will be performed on data from
      the COPD population only. For other outcome measures, final analyses will be performed on
      data merged from COPD patients and healthy subjects. An important rationale behind
      implementing healthy control subjects is to increase the statistical power of outcome
      measures unrelated to COPD epidemiology, which are of general relevance to physiological
      adaptation to strength training. In a related set of analyses, we will perform between-groups
      comparisons, including multivariate analyses. We will also compare the efficacy of high- and
      low-resistance strength training in COPD patients and healthy control subjects. The two
      training modalities are expected to result in similar muscular adaptations.

      In general, baseline vitamin D levels in blood, measured as 25(OH)D, is anticipated to be a
      determinant of the efficacy of the strength training intervention. In response to vitamin D3
      supplementation, individuals with low baseline levels of 25(OH)D are expected to display more
      pronounced changes in biological active vitamin D, leading to more pronounced changes in
      functional and biological outcome measures in response to strength training. In contrast,
      supplementation may not lead to further elevation of blood 25(OH)D levels in individuals with
      high baseline levels, essentially meaning that vitamin D3 ingestion will be leveled out by or
      exceeded by the elimination of vitamin D derivatives. In these individuals, vitamin D3
      ingestion will not have an additive effect on functional and biological outcome measures in
      response to strength training. To assess individual variation in vitamin D responses, data on
      functional and biological variables will be divided into quartiles based on baseline
      25(OH)D-levels, whereupon comparisons will be made between low-end and high-end quartiles.
      Individual variation in responses to vitamin D supplementation and strength training will
      also be assessed using a mixed model approach.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Muscle size</measure>
    <time_frame>Changes from before to after the strength training intervention (week 19 to week 28)</time_frame>
    <description>Muscle cell cross-sectional area measured in biopsies from m. vastus lateralis using immunohistochemistry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Muscle phenotype</measure>
    <time_frame>Changes from before to after the strength training intervention (week 19 to week 28)</time_frame>
    <description>Muscle fiber type composition measured in biopsies from m. vastus lateralis using immunohistochemistry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lung function</measure>
    <time_frame>Changes from before to after the strength training intervention (week 19 to week 28)</time_frame>
    <description>Lung function measured using spirometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>One-legged cycling</measure>
    <time_frame>Changes from before to after the strength training intervention (week 19 to week 28)</time_frame>
    <description>Performance indicies measured during an incremental one-legged cycling test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hormones in blood</measure>
    <time_frame>Changes over the course of the intervention (week 0 to 28)</time_frame>
    <description>Levels of hormones in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokines in blood</measure>
    <time_frame>Changes over the course of the intervention (week 0 to 28)</time_frame>
    <description>Levels of cytokines in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steroids in skeletal muscle</measure>
    <time_frame>Changes over the course of the intervention (week 0 to 28)</time_frame>
    <description>Levels of steroids in m. vastus lateralis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Androgen-converting enzymes in skeletal muscle</measure>
    <time_frame>Changes from before to after the strength training intervention (week 19 to week 28)</time_frame>
    <description>Levels of androgen-converting enzymes in m. vastus lateralis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gene expression in skeletal muscle</measure>
    <time_frame>Changes from before to after the strength training intervention (week 19 to week 28)</time_frame>
    <description>RNA (e.g. messenger RNA, ribosomal RNA, microRNA, long non-coding RNA) abundances in m. vastus lateralis, measured both as single genes and at the level of the transcriptome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gene expression in skeletal muscle</measure>
    <time_frame>Changes from before to after familiarization to strength training (week 15 to week 17)</time_frame>
    <description>RNA (e.g. messenger RNA, ribosomal RNA, microRNA, long non-coding RNA) abundances in m. vastus lateralis, measured both as single genes and at the level of the transcriptome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protein abundances in skeletal muscle</measure>
    <time_frame>Changes from before to after the strength training intervention (week 19 to week 28)</time_frame>
    <description>Levels of proteins and their modification status (e.g. phosphorylation) in m. vastus lateralis, measured at the level of single proteins and at the level of the proteome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protein abundances in skeletal muscle</measure>
    <time_frame>Changes from before to after familiarization to strength training (week 15 to week 17)</time_frame>
    <description>Levels of proteins and their modification status (e.g. phosphorylation) in m. vastus lateralis, measured at the level of single proteins and at the level of the proteome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vitamin D in blood</measure>
    <time_frame>Changes over the course of the intervention (week 0 to 28)</time_frame>
    <description>Levels of vitamin D in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Step test</measure>
    <time_frame>Changes from before to after the strength training intervention (week 19 to week 28)</time_frame>
    <description>Performance and performance indicies measured during a 6 minutes step test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pasient-reported outcome measures, generic</measure>
    <time_frame>Changes from before to after the strength training intervention (week 19 to week 28)</time_frame>
    <description>Pasient-related outcome measures assessed using the generic survey SF-36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pasient-reported outcome measures, COPD-specific</measure>
    <time_frame>Changes from before to after the strength training intervention (week 19 to week 28)</time_frame>
    <description>COPD-specific pasient-reported outcome assessed using COPD assessment test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body mass composition</measure>
    <time_frame>Changes from before to after the strength training intervention (week 19 to week 28)</time_frame>
    <description>Body mass composition measured using Dual-energy X-ray absorptiometry (DXA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bilateral upper body maximal strength</measure>
    <time_frame>Changes from before to after the strength training intervention (week 19 to week 28)</time_frame>
    <description>The ability of muscles of the upper body to exert maximal force during dynamic movements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grip strength</measure>
    <time_frame>Changes from before to after the strength training intervention (week 19 to week 28)</time_frame>
    <description>Isometric hand grip strength</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sit-to-stand test</measure>
    <time_frame>Changes from before to after the strength training intervention (week 19 to week 28)</time_frame>
    <description>Performance and performance indicies measured during a sit-to-stand test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unilateral lower body maximal muscle strength</measure>
    <time_frame>Changes from before to after the strength training intervention (week 19 to week 28)</time_frame>
    <description>The ability of muscles of the lower body to exert maximal force during dynamic movements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unilateral lower body muscle endurance</measure>
    <time_frame>Changes from before to after the strength training intervention (week 19 to week 28)</time_frame>
    <description>The ability of muscles of the lower body to perform repeated dynamic contractions at a specified submaximal load to exhaustion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bilateral upper body muscle endurance</measure>
    <time_frame>Changes from before to after the strength training intervention (week 19 to week 28)</time_frame>
    <description>The ability of muscles of the upper body to perform repeated dynamic contractions at a specified submaximal load to exhaustion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unilateral lower body isokinetic muscle strength</measure>
    <time_frame>Changes from before to after the strength training intervention (week 19 to week 28)</time_frame>
    <description>The ability of muscles of the lower body to exert maximal force during isokinetic movements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily life activity level</measure>
    <time_frame>Changes from before to after the intervention (week 0 to week 28)</time_frame>
    <description>Daily life activity level measured using accelerometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle cell biological traits</measure>
    <time_frame>Changes from before to after the strength training intervention (week 19 to week 28)</time_frame>
    <description>Muscle cell biological traits, including numbers of myonuclei, satelitte cells and capillaries, measured in biopsies from m. vastus lateralis using immunohistochemistry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle mitochondrial quantities</measure>
    <time_frame>Changes from before to after the strength training intervention (week 19 to week 28)</time_frame>
    <description>Mitochondrial quantities measured in biopsies from m. vastus lateralis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle mitochondrial functions</measure>
    <time_frame>Changes from before to after the strength training intervention (week 19 to week 28)</time_frame>
    <description>Mitochondrial functions measured in biopsies from m. vastus lateralis</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Training diary</measure>
    <time_frame>Measured over the course of the strength training familiarization period and the strength training intervention (week 15 to week 28)</time_frame>
    <description>Training diary containing information about type of training, duration of training and training intensity</description>
  </other_outcome>
  <other_outcome>
    <measure>Dietary registration</measure>
    <time_frame>Registred at one time point during the strength training intervention (~week 23, registred over four days)</time_frame>
    <description>Detailed registration of food intake</description>
  </other_outcome>
  <other_outcome>
    <measure>Self-reported information on lifestyle-related aspects</measure>
    <time_frame>Measured over the course of the intervention (week 0 to week 28)</time_frame>
    <description>Disease, symptoms, injury, vitamin D-intake, time spent outdoors, solarium, training background, smoking, etc</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Vitamin D3+str.training, COPD &amp; Healthy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin D3 capsules for 30 weeks:
weeks 1-2: 10000 IU/day (equivalent to 250 ug), accompanied by 1000 mg Ca2+
weeks 3-30: 2000 IU/day (equivalent to 50 ug), accompanied by 1000 mg Ca2+
Progressive unilateral strength training of the legs for 3+10 weeks (weeks 15-28); leg 1 = high-load training, leg 2 = low-load training, allocated to left and right foot in a randomized manner:
weeks 15-17, familiarization period
week 18, test period
weeks 19-28, intervention period
weeks 29-30, test period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo+str.training, COPD &amp; Healthy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules for 30 weeks (the number of capsules ingested each day match those of the vitamin D3 group)
Progressive unilateral strength training of the legs for 3+10 weeks (weeks 15-28); leg 1 = high-load training, leg 2 = low-load training, allocated to left and right foot in a randomized manner:
weeks 15-17, familiarization period
week 18, test period
weeks 19-28, intervention period
weeks 29-30, test period</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>Vitamin D3 dissolved in olive oil, encapsuled</description>
    <arm_group_label>Vitamin D3+str.training, COPD &amp; Healthy</arm_group_label>
    <other_name>cholecalciferol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Olive oil, encapsuled</description>
    <arm_group_label>Placebo+str.training, COPD &amp; Healthy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        COPD group

        Inclusion Criteria:

          -  Stable COPD at GOLD stage II or III, FEV1/FVC &lt; 0.7 and FEV1 &lt;80% and &gt;30% of
             predicted

          -  &gt;45 years of age

        Exclusion Criteria:

          -  Unstable cardiovascular disease

          -  Chronic granulomatous

          -  Known active malignant disease within last 5 years

          -  Physically disabling muscloskeletal diseases

          -  Peroral use of steroids within last 2 months

          -  Serious psychiatric comorbidity

          -  Less than 4 weeks since last return t o habit ual condit ion from exacerbation

          -  Failing to understand Norwegian literary or verbally

          -  Medical record diagnosis of asthma

          -  More than one bout of strength training per week during the last 6 months leading up
             to the project

        Healthy control group

        Inclusion Criteria:

        - &gt;45 years of age

        Exclusion Criteria:

          -  COPD

          -  Unstable cardiovascular disease

          -  Chronic granulomatous

          -  Known active malignant disease within last 5 years

          -  Physically disabling muscloskeletal diseases

          -  Peroral use of steroids within last 2 months

          -  Serious psychiatric comorbidity

          -  Failing to understand Norwegian literary or verbally

          -  Medical record diagnosis of asthma

          -  More than one bout of strength training per week during the last 6 months leading up
             to the project
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Knut Sindre MÃ¸lmen, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inland Norway University of Applied Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inland Norway University of Applied Sciences</name>
      <address>
        <city>Lillehammer</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2015</study_first_submitted>
  <study_first_submitted_qc>November 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2015</study_first_posted>
  <last_update_submitted>December 8, 2017</last_update_submitted>
  <last_update_submitted_qc>December 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cachexia</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Muscle</keyword>
  <keyword>Strength training</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified data will be made available to the academic community through the general biobank &quot;The Trainsome - effects of exercise and environment on human cells&quot; (REK-2013/2045, Regional Comitees for Medical and Health Research Ethics South East). Data will be available on request and will be restricted to scientists and/or projects with a sound scientific purpose and rationale.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

